GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028

  • You are here:
  • Home
  • Reports
  • GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028

GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028

The global cystic fibrosis therapeutics market is anticipated to grow at a CAGR of 10.04% between 2020 and 2028, generating a revenue of $11.95 billion by 2028. Cystic fibrosis is a hereditary disorder, which majorly affects the lungs and other body parts such as the pancreas, liver, and kidney. It is caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028

Global Cystic Fibrosis Therapeutics Market by Route of Administration (Inhale, Oral) by Drug Class (CFTR Modulators, Bronchodilators, Mucolytic, Pancreatic Enzyme Supplements) and by Geography.

Request free sample

The global cystic fibrosis therapeutics market is anticipated to grow at a CAGR of 10.04% between 2020 and 2028, generating a revenue of $11.95 billion by 2028. Cystic fibrosis is a hereditary disorder, which majorly affects the lungs and other body parts such as the pancreas, liver, and kidney. It is caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

The global cystic fibrosis therapeutics market growth is augmented by the following factors:

  • Advancements in the cystic fibrosis therapeutics treatment
  • Increasing incidence of cystic fibrosis (CF)
  • Rise in the R&D of novel cystic fibrosis therapeutics

The important factors driving the global cystic fibrosis therapeutics market growth are advancements in the cystic fibrosis therapeutics treatment and increasing incidence of cystic fibrosis (CF). The introduction of new drugs is now widely being used for the treatment of cystic fibrosis, and many other CFTR drugs are under clinical trials. In recent years, a significant rise in the incidence rate of cystic fibrosis has been witnessed across the globe. Thereby, a rise in the incidence of CF across the globe is anticipated to drive the market for cystic fibrosis therapeutics in the near future.

In 2019, the dominating drug class was CFTR modulators, contributing about 64.74% of the revenue share with regard to cystic fibrosis therapeuticsBronchodilators drug class captured around 15.51% of the revenue share in 2019. CFTR modulator drugs are currently the major focus area of drug development against cystic fibrosis. These drugs are being measured as effective therapeutics for treating the disease. The three main categories of modulators are correctors, potentiators, and amplifiers. Bronchodilators are usually recommended as a first‐line treatment of lung disease in people with cystic fibrosis. Albuterol (brand names Ventolin and Proventalin), Xopenex (levalbuterol), and Combivent, a combination of ipratropium bromide and albuterol, are bronchodilators used to treat bronchospasms caused due to cystic fibrosis.

Stringent regulations and low awareness among developing economies are the major factors hindering cystic fibrosis therapeutics market analysis. The medical device industry across the globe has become very competitive. To handle the competition efficiently and to gain a better market share, most manufacturers aim at new designs and innovative devices to be introduced into the market with enhanced performance. The incidence rate of CF is found to be lower in developing countries such as the Asia Pacific as compared to the North American and European countries. Though the incidence rate of Asia Pacific countries such as India, China, Japan, among others, is lower as compared to Caucasians, the registries of the disease are anticipated to be lower than the actual incidence.

The report on the global cystic fibrosis therapeutics market includes segmentation analysis on the basis of route of administration and drug class.

Route of administration is segmented into:

  • Inhale
  • Oral

Drug Class is segmented into:

  • CFTR Modulators
  • Bronchodilators
  • Mucolytic
  • Pancreatic Enzyme Supplements

Geographically, the global cystic fibrosis therapeutics market has been segmented on the basis of four major regions, which includes:

  • Europe: the United Kingdom, Germany, France, Italy, Russia, Belgium, Poland, and the Rest of Europe
  • North America: the United States and Canada
  • Asia Pacific: China, India, Japan, South Korea, Thailand, Indonesia, Vietnam, Australia & New Zealand, and the Rest of Asia Pacific
  • Rest of World: Latin America, the Middle East & Africa

In 2019, Europe captured the largest market share of 39.03%, in terms of revenue. The cystic fibrosis therapeutics market trend in Europe is expected to hold the largest share by 2028, and is projected to grow at a fast pace during the forecast period, owing to a surge in cystic fibrosis incidence. For instance, according to the European Cystic Fibrosis Society in 2016, 38,985 individuals were suffering from cystic fibrosis. Among these, 10,336 patients were from the UK. A rise in awareness among patients in the United Kingdom regarding early diagnosis of cystic fibrosis is anticipated to boost the market growth. Moreover, an upsurge in governmental funding for invention and an increase in the subsidy of developments for R&D of numerous CFS drugs further fuel the market development in this region.

The distinguished market players of the global cystic fibrosis therapeutics market are:

  • Hoffmann-La Roche
  • Gilead Sciences Inc
  • GlaxoSmithKline PLC
  • Novartis AG
  • AbbVie Inc
  • Others

Key strategies adopted by some of the cystic fibrosis therapeutics companies are:

In November 2019, AbbVie and Harpoon Therapeutics announced option collaboration and licensing to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC, and expand existing discovery collaboration. Further, in September 2019, F. Hoffmann-La Roche and KAHR Medical collaborated to assess the potential of DSP107 and atezolizumab in NSCLC patients who are refractory to PD1/PD-L1 inhibitors.

Key findings of the global cystic fibrosis therapeutics market are:

  • There is the availability of personalized drug therapy.
  • Molecular prosthetics is utilized for the treatment of cystic fibrosis.
  • The inhale route is the majorly used route of administration.
  • CFTR Modulators are the fastest-growing drug class.
  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • MARKET DEFINITION
    •    KEY DRIVERS
      • ADVANCEMENTS IN THE CYSTIC FIBROSIS THERAPEUTICS TREATMENT
      • INCREASING INCIDENCE OF CYSTIC FIBROSIS (CF)
      • RISE IN THE R&D OF NOVEL CYSTIC FIBROSIS THERAPEUTICS
    •    KEY RESTRAINTS
      • STRINGENT REGULATION
      • LOW AWARENESS AMONG DEVELOPING ECONOMIES
  1. KEY ANALYTICS
    •    PORTER’S FIVE FORCE ANALYSIS
      • THREAT OF NEW ENTRY
      • THREAT OF SUBSTITUTION
      • BUYER’S POWER
      • SUPPLIER’S POWER
      • COMPETITIVE RIVALRY
    • PESTEL ANALYSIS
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHTS
  2. MARKET BY ROUTE OF ADMINISTRATION
    • INHALE
    • ORAL
  3. MARKET BY DRUG CLASS
    • CFTR MODULATORS
    • BRONCHODILATORS
    • MUCOLYTIC
    • PANCREATIC ENZYME SUPPLEMENTS
  4. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    •    EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    •    ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • AUSTRALIA & NEW ZEALAND
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
    •    REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA
  1. COMPANY PROFILES
    • ABBOTT LABORATORIES
    • ABBVIE INC
    • AGILENT TECHNOLOGIES INC
    • ALLERGAN PLC
    • HOFFMANN-LA ROCHE
    • GILEAD SCIENCES INC
    • GLAXOSMITHKLINE PLC
    • JOHNSON & JOHNSON
    • MYLAN N.V
    • NOVARTIS AG
    • PERKINELMER
    • PFIZER INC
    • PHARMAXIS LTD
    • TEVA PHARMACEUTICAL INDUSTRIES LTD
    • VERTEX PHARMACEUTICALS INCORPORATED

TABLE LIST

TABLE 1: MARKET SNAPSHOT – VETERINARY VACCINE

TABLE 2: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 3: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 4: GLOBAL INHALE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 5: GLOBAL INHALE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 6: GLOBAL ORAL MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 7: GLOBAL ORAL MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 8: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 9: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 10: GLOBAL CFTR MODULATORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 11: LIST OF CFTR MODULATORS GENERIC AND BRAND NAME

TABLE 12: GLOBAL CFTR MODULATORS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 13: GLOBAL BRONCHODILATORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 14: LIST OF BRONCHODILATORS GENERIC AND BRAND NAME

TABLE 15: GLOBAL BRONCHODILATORS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 16: GLOBAL MUCOLYTIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 17: LIST OF MUCOLYTICS GENERIC AND BRAND NAME

TABLE 18: GLOBAL MUCOLYTIC MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 19: GLOBAL PANCREATIC ENZYME SUPPLEMENTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 20: GLOBAL PANCREATIC ENZYME SUPPLEMENTS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 21: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 22: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 23: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 24: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 25: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 26: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 27: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 28: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 29: REST OF WORLD CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 30: REST OF WORLD CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

FIGURE LIST          

FIGURE 1: PORTER’S FIVE FORCES ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, IN 2019

FIGURE 6: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY INHALE, 2020-2028 (IN $ MILLION)

FIGURE 7: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ORAL, 2020-2028 (IN $ MILLION)

FIGURE 8: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, IN 2019

FIGURE 9: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY CFTR MODULATORS, 2020-2028 (IN $ MILLION)

FIGURE 10: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY BRONCHODILATORS, 2020-2028 (IN $ MILLION)

FIGURE 11: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY MUCOLYTIC, 2020-2028 (IN $ MILLION)

FIGURE 12: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY PANCREATIC ENZYME SUPPLEMENTS, 2020-2028 (IN $ MILLION)

FIGURE 13: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 14: THE UNITED STATES CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 15: CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 16: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 17: THE UNITED KINGDOM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 18: FRANCE CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 19: GERMANY CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 20: ITALY CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 21: RUSSIA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 22: BELGIUM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 23: POLAND CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 24: REST OF EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 25: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 26: CHINA CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)

FIGURE 27: JAPAN CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)

FIGURE 28: INDIA CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)

FIGURE 29: AUSTRALIA & NEW ZEALAND CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)

FIGURE 30: SOUTH KOREA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 31: THAILAND CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 32: INDONESIA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 33: VIETNAM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 34: REST OF ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 35: REST OF WORLD CYSTIC FIBROSIS THERAPEUTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 36: LATIN AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 37: MIDDLE EAST & AFRICA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

  1. MARKET BY ROUTE OF ADMINISTRATION
    • INHALE
    • ORAL
  2. MARKET BY DRUG CLASS
    • CFTR MODULATORS
    • BRONCHODILATORS
    • MUCOLYTIC
    • PANCREATIC ENZYME SUPPLEMENTS
  3. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • AUSTRALIA & NEW ZEALAND
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now